References
Abbaspour Kasgari, H., Moradi, S., Shabani, A.M., Babamahmoodi, F., Davoudi Badabi, A.R., Davoudi, L., et al. (2020). Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J. Antimicrob. Chemother. 75 : 3373–3378.
Abu Esba, L.C., Alqahtani, R.A., Thomas, A., Shamas, N., Alswaidan, L., and Mardawi, G. (2020). Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study. Infect. Dis. Ther. 1–16.
Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., et al. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9 :.
Ali, N. (2020). Role of vitamin D in preventing of COVID-19 infection, progression and severity. J. Infect. Public Health 13 : 1373–1380.
Alshaeri, H.K., and Natto, Z.S. (2020). A contemporary look at COVID-19 medications: Available and potentially effective drugs. Eur. Rev. Med. Pharmacol. Sci. 24 : 9188–9195.
American Association for Clinical Chemistry (2020). Disseminated Intravascular Coagulation in COVID-19—Insights From the Front Lines | AACC.org.
American Society of Hematology (2020a). COVID-19 and Coagulopathy - Hematology.org.
American Society of Hematology (2020b). COVID-19 and VTE-Anticoagulation - Hematology.org.
Angus, D.C., Derde, L., Al-Beidh, F., Annane, D., Arabi, Y., Beane, A., et al. (2020). Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 : 1317–1329.
Annane, D., Heming, N., Grimaldi-Bensouda, L., Frémeaux-Bacchi, V., Vigan, M., Roux, A.L., et al. (2020). Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine 28 : 100590.
ANSM (2019). Anti-inflammatoires non stéroïdiens (AINS) et complications infectieuses graves - Point d’Information actualisé le 20/05/2020 - ANSM : Agence nationale de sécurité du médicament et des produits de santé.
Arabi, Y.M., Hajeer, A.H., Luke, T., Raviprakash, K., Balkhy, H., Johani, S., et al. (2016). Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg. Infect. Dis.22 : 1554–1561.
Asakura, H., and Ogawa, H. (2020). COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int. J. Hematol. 1 : 3.
AstraZeneca (2020). AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK.
Atallah, B., Mallah, S.I., and AlMahmeed, W. (2020). Anticoagulation in COVID-19. Eur. Hear. J. - Cardiovasc. Pharmacother. 6 : 260–261.
Ayerbe, L., Risco, C., and Ayis, S. (2020). The association between treatment with heparin and survival in patients with Covid-19. J. Thromb. Thrombolysis 50 : 298–301.
Baden, L.R., Sahly, H.M. El, Essink, B., Kotloff, K., Frey, S., Novak, R., et al. (2020). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. NEJMoa2035389.
Bairi, K. El, Trapani, D., Petrillo, A., Page, C. Le, Zbakh, H., Daniele, B., et al. (2020). Repurposing anticancer drugs for the management of COVID-19. Eur. J. Cancer 141 : 40–61.
Bancos, S., Bernard, M.P., Topham, D.J., and Phipps, R.P. (2009). Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell. Immunol. 258 : 18–28.
Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., et al. (2020). Remdesivir for the Treatment of Covid-19 — Final Report. N. Engl. J. Med.
Benucci, M., Giannasi, G., Cecchini, P., Gobbi, F.L., Damiani, A., Grossi, V., et al. (2020). COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients. J. Med. Virol. 92 : 2368–2370.
Bhattacharyya, A., Kumar, S., Sarma, P., Kaur, H., Prajapat, M., Shekhar, N., et al. (2020). Safety and efficacy of lopinavir/ ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian J. Pharmacol. 52 : 313–323.
Bian, H., Zheng, Z.-H., Wei, D., Zhang, Z., Kang, W.-Z., Hao, C.-Q., et al. (2020). Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. MedRxiv 2020.03.21.20040691.
Bianconi, V., Violi, F., Fallarino, F., Pignatelli, P., Sahebkar, A., and Pirro, M. (2020). Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? Drugs 80 : 1383–1396.
Bloch, E.M., Shoham, S., Casadevall, A., Sachais, B.S., Shaz, B., Winters, J.L., et al. (2020). Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. 130 : 2757–2765.
Boulware, D.R., Pullen, M.F., Bangdiwala, A.S., Pastick, K.A., Lofgren, S.M., Okafor, E.C., et al. (2020). A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N. Engl. J. Med. 383 : 517–525.
Boyle, A.J., Gangi, S. Di, Hamid, U.I., Mottram, L.J., McNamee, L., White, G., et al. (2015). Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: A prospective analysis. Crit. Care19 :.
Bruce, E., Barlow-Pay, F., Short, R., Vilches-Moraga, A., Price, A., McGovern, A., et al. (2020). Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19. J. Clin. Med. 9 : 2586.
Buijsers, B., Yanginlar, C., Maciej-Hulme, M.L., Mast, Q. de, and Vlag, J. van der (2020). Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine 59 : 102969.
Cacciapuoti, S., Rosa, A. De, Gelzo, M., Megna, M., Raia, M., Pinchera, B., et al. (2020). Immunocytometric analysis of COVID patients: A contribution to personalized therapy? Life Sci. 261 : 118355.
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., et al. (2020). Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering.
Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., and Wagstaff, K.M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178 :.
Camprubí, D., Almuedo-Riera, A., Martí-Soler, H., Soriano, A., Hurtado, J.C., Subirà, C., et al. (2020). Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One 15 : e0242184.
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., and Goletti, D. (2020a). Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J. Infect. 81 : 318–356.
Cantini, F., Niccoli, L., Nannini, C., Matarrese, D., Natale, M.E. Di, Lotti, P., et al. (2020b). Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J. Infect. 81 : 647–679.
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., et al. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 382 : 1787–1799.
Capoluongo, E.D., Amato, F., and Castaldo, G. (2020). The friendly use of chloroquine in the COVID-19 disease: A warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Clin. Chem. Lab. Med. 58 : 1162–1164.
Capuano, A., Rossi, F., and Paolisso, G. (2020a). Covid-19 Kills More Men Than Women: An Overview of Possible Reasons. Front. Cardiovasc. Med.7 : 131.
Capuano, A., Scavone, C., Racagni, G., and Scaglione, F. (2020b). NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators? Pharmacol. Res. 157 : 104849.
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., et al. (2020a). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.
CHEN, J., LIU, D., LIU, L., LIU, P., XU, Q., XIA, L., et al. (2020). A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 49 : 1–10.
Chen, J., Xia, L., Liu, L., Xu, Q., Ling, Y., Huang, D., et al. (2020b). Antiviral activity and safety of darunavir/Cobicistat for the treatment of COVID-19. Open Forum Infect. Dis. 7 :.
Chen, P., Nirula, A., Heller, B., Gottlieb, R.L., Boscia, J., Morris, J., et al. (2020c). SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med.
Chen, W., Janz, D.R., Bastarache, J.A., May, A.K., O’Neal, H.R., Bernard, G.R., et al. (2015). Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: A propensity-adjusted analysis. Crit. Care Med. 43 : 801–807.
Cheng, Y., Wong, R., Soo, Y.O.Y., Wong, W.S., Lee, C.K., Ng, M.H.L., et al. (2005). Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24 : 44–46.
Choi, M.J., Kang, M., Shin, S.Y., Noh, J.Y., Cheong, H.J., Kim, W.J., et al. (2020). Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. Int. J. Infect. Dis.
Chow, J.H., Khanna, A.K., Kethireddy, S., Yamane, D., Levine, A., Jackson, A.M., et al. (2020). Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19. Anesth. Analg. Publish Ah :
Cingolani, A., Tummolo, A.M., Montemurro, G., Gremese, E., Larosa, L., Cipriani, M.C., et al. (2020). Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection48 : 767–771.
Cordon-Cardo, C., Pujadas, E., Wajnberg, A., Sebra, R., Patel, G., Firpo-Betancourt, A., et al. (2020). COVID-19: Staging of a New Disease. Cancer Cell 38 : 594–597.
D’avolio, A., Avataneo, V., Manca, A., Cusato, J., Nicolò, A. De, Lucchini, R., et al. (2020). 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients12 :.
Deeks, E.D. (2018). Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs 78 : 1013–1024.
Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., et al. (2020). Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J. Infect. 81 : e1–e5.
Dequin, P.F., Heming, N., Meziani, F., Plantefève, G., Voiriot, G., Badié, J., et al. (2020). Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support among Critically Ill Patients with COVID-19: A Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 : 1298–1306.
Doi, K., Ikeda, M., Hayase, N., Moriya, K., Morimura, N., Maehara, H., et al. (2020). Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit. Care 24 :.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., et al. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. U. S. A. 117 : 9490–9496.
Eli Lilly and Company Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19 | Eli Lilly and Company.
Elsawah, H.K., Elsokary, M.A., Abdallah, M.S., and ElShafie, A.H. (2020). Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: Systematic review and meta‐analysis including network meta‐analysis. Rev. Med. Virol.
Erlich, J.M., Talmor, D.S., Cartin-Ceba, R., Gajic, O., and Kor, D.J. (2011). Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: A population-based cohort study. Chest 139 : 289–295.
Eslami, G., Mousaviasl, S., Radmanesh, E., Jelvay, S., Bitaraf, S., Simmons, B., et al. (2020). The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J. Antimicrob. Chemother.75 : 3366–3372.
European Medicine agency (2020). COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes | European Medicines Agency.
European Medicine Agency Update on remdesivir - EMA will evaluate new data from Solidarity trial | European Medicines Agency.
European Medicine Agency (2020a). COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine.
European Medicine Agency (2020b). COVID-19: reminder of the risks of chloroquine and hydroxychloroquine | European Medicines Agency.
European Medicine Agency (2020c). EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation | European Medicines Agency.
European Medicine Agency (2020d). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 November 2020 | European Medicines Agency.
Favalli, E.G., Biggioggero, M., Maioli, G., and Caporali, R. (2020). Baricitinib for COVID-19: a suitable treatment? Lancet Infect. Dis.20 : 1012–1013.
Fehr, A.R., and Perlman, S. (2015). Coronaviruses: An overview of their replication and pathogenesis. In Coronaviruses: Methods and Protocols, (Springer New York), pp 1–23.
Ferrara, N., Hillan, K.J., and Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333 : 328–335.
Food and Drug Administration Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 | FDA.
Gao, G., Wang, A., Wang, S., Qian, F., Chen, M., Yu, F., et al. (2020). Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. J. Acquir. Immune Defic. Syndr. 85 : 239–243.
Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 56 : 105949.
Goldman, J.D., Lye, D.C.B., Hui, D.S., Marks, K.M., Bruno, R., Montejano, R., et al. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N. Engl. J. Med.
Gozzo, L., Viale, P., Longo, L., Vitale, D.C., and Drago, F. (2020). The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review. Front. Pharmacol. 11 :.
Gralinski, L.E., Sheahan, T.P., Morrison, T.E., Menachery, V.D., Jensen, K., Leist, S.R., et al. (2018). Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio9 :.
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., et al. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 382 : 2327–2336.
Gremese, E., Cingolani, A., Bosello, S.L., Alivernini, S., Tolusso, B., Perniola, S., et al. (2020). Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine 27 :.
Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen, S.D., Jin, H.J., et al. (2020a). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status. Mil. Med. Res. 7 :.
Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen, S.D., Jin, H.J., et al. (2020b). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 7 : 11.
Hastie, C.E., Mackay, D.F., Ho, F., Celis-Morales, C.A., Katikireddi, S.V., Niedzwiedz, C.L., et al. (2020). Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab. Syndr. Clin. Res. Rev.14 : 561–565.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell181 : 271-280.e8.
Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., et al. (2020a). Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N. Engl. J. Med.
Horby, P.W., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Emberson, J., et al. (2020b). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 396 : 1345–1352.
Huang, M., Tang, T., Pang, P., Li, M., Ma, R., Lu, J., et al. (2020). Treating COVID-19 with Chloroquine. J. Mol. Cell Biol. 12 : 322–325.
Hung, I.F.N., Lung, K.C., Tso, E.Y.K., Liu, R., Chung, T.W.H., Chu, M.Y., et al. (2020). Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395 : 1695–1704.
Italian Medicine Agency RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO.
Italian Medicine Agency (2020a). COVID-19: STUDIO RANDOMIZZATO ITALIANO, NESSUN BENEFICIO DAL TOCILIZUMAB.
Italian Medicine Agency (2020b). Idrossiclorochina nella terapia dei pazienti adulti con COVID-19 .
Ivashchenko, A.A., Dmitriev, K.A., Vostokova, N. V, Azarova, V.N., Blinow, A.A., Egorova, A.N., et al. (2020). AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin. Infect. Dis.
Iwasaka, S., Shono, Y., Tokuda, K., Nakashima, K., Yamamoto, Y., Maki, J., et al. (2020). Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. J. Infect. Chemother. 26 : 1319–1323.
Janssen (2020). Janssen begins second Phase III Covid-19 vaccine trial .
Jeronimo, C.M.P., Farias, M.E.L., Val, F.F.A., Sampaio, V.S., Alexandre, M.A.A., Melo, G.C., et al. (2020). Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin. Infect. Dis.
Jovic, T.H., Ali, S.R., Ibrahim, N., Jessop, Z.M., Tarassoli, S.P., Dobbs, T.D., et al. (2020). Could vitamins help in the fight against covid-19? Nutrients 12 : 1–30.
Karolyi, M., Pawelka, E., Mader, T., Omid, S., Kelani, H., Ely, S., et al. (2020). Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort. Wien. Klin. Wochenschr.
Khamis, F., Naabi, H. Al, Lawati, A. Al, Ambusaidi, Z., Sharji, M. Al, Barwani, U. Al, et al. (2020). Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia. Int. J. Infect. Dis.
Kim, E.J., Choi, S.H., Park, J.S., Kwon, Y.S., Lee, J., Kim, Y., et al. (2020). Use of darunavir-cobicistat as a treatment option for critically ill patients with sars-cov-2 infection. Yonsei Med. J. 61 : 826–830.
Klok, F.A., Kruip, M.J.H.A., Meer, N.J.M. van der, Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., et al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res.191 : 145–147.
Kor, D.J., Carter, R.E., Park, P.K., Festic, E., Banner-Goodspeed, V.M., Hinds, R., et al. (2016). Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department the LIPS-a randomized clinical trial. JAMA - J. Am. Med. Assoc. 315 : 2406–2414.
Kor, D.J., Erlich, J., Gong, M.N., Malinchoc, M., Carter, R.E., Gajic, O., et al. (2011). Association of prehospitalization aspirin therapy and acute lung injury: Results of a multicenter international observational study of at-risk patients. Crit. Care Med. 39 : 2393–2400.
Kraft, C.S., Hewlett, A.L., Koepsell, S., Winkler, A.M., Kratochvil, C.J., Larson, L., et al. (2015). The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin. Infect. Dis. 61 : 496–502.
Laurence, J., Mulvey, J.J., Seshadri, M., Racanelli, A., Harp, J., Schenck, E.J., et al. (2020). Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin. Immunol. 219 :.
Lecronier, M., Beurton, A., Burrel, S., Haudebourg, L., Deleris, R., Marec, J. Le, et al. (2020). Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: An opportunistic retrospective analysis. Crit. Care 24 :.
Leppkes, M., Knopf, J., Naschberger, E., Lindemann, A., Singh, J., Herrmann, I., et al. (2020). Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 58 :.
Leuchte, H.H., Baezner, C., Baumgartner, R.A., Bevec, D., Bacher, G., Neurohr, C., et al. (2008). Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur. Respir. J. 32 : 1289–1294.
Levi, M., Thachil, J., Iba, T., and Levy, J.H. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol.7 : e438–e440.
Lewis, T.C., Adhikari, S., Tatapudi, V., Holub, M., Kunichoff, D., Troxel, A.B., et al. (2020). A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019. Crit. Care Explor. 2 : e0283.
Li, H., Liu, L., Zhang, D., Xu, J., Dai, H., Tang, N., et al. (2020a). SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet395 : 1517–1520.
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., et al. (2020b). Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 : 460–470.
Li, T., Lu, H., and Zhang, W. (2020c). Clinical observation and management of COVID-19 patients. Emerg. Microbes Infect. 9 : 687–690.
Li, X., and Ma, X. (2017). The role of heparin in sepsis: much more than just an anticoagulant. Br. J. Haematol. 179 : 389–398.
Li, Y., Xie, Z., Lin, W., Cai, W., Wen, C., Guan, Y., et al. (2020d). Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. Med 0 :
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S.P., Carter, L.J., et al. (2020a). Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 6 : 315–331.
Liu, S.T.H., Lin, H.M., Baine, I., Wajnberg, A., Gumprecht, J.P., Rahman, F., et al. (2020b). Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nat. Med.26 : 1708–1713.
Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., et al. (2020). Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb. Res. 191 : 9–14.
Lother, S.A., Abassi, M., Agostinis, A., Bangdiwala, A.S., Cheng, M.P., Drobot, G., et al. (2020). Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Can. J. Anesth. 67 : 1201–1211.
Lou, Y., Liu, L., Yao, H., Hu, X., Su, J., Xu, K., et al. (2020). Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. Eur. J. Pharm. Sci. 105631.
Marietta, M., Ageno, W., Artoni, A., Candia, E. De, Gresele, P., Marchetti, M., et al. (2020). COVID-19 and haemostasis: A position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 18 : 167–169.
Mascolo, A., Berrino, P.M., Gareri, P., Castagna, A., Capuano, A., Manzo, C., et al. (2018). Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology 26 : 1141–1149.
Mascolo, A., Scavone, C., Rafaniello, C., Ferrajolo, C., Racagni, G., Berrino, L., et al. (2020). Renin-angiotensin system and coronavirus disease 2019: A narrative review. Front. Cardiovasc. Med. 7 :.
McGonagle, D., O’Donnell, J.S., Sharif, K., Emery, P., and Bridgewood, C. (2020). Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2 : e437–e445.
Meyer, S. De, Bojkova, D., Cinatl, J., Damme, E. Van, Buyck, C., Loock, M. Van, et al. (2020). Lack of antiviral activity of darunavir against SARS-CoV-2. Int. J. Infect. Dis. 97 : 7–10.
Ministère de la Santé (2020). Liste des messages d’alertes.
Mitchell, F. (2020). Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 8 : 570.
Moderna (2020). Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization | Moderna, Inc.
Molina, J.M., Delaugerre, C., Goff, J. Le, Mela-Lima, B., Ponscarme, D., Goldwirt, L., et al. (2020). No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med. Mal. Infect. 50 : 384.
monde, Le (2020). Le ministre de la santé déconseille l’ibuprofène contre le coronavirus.
Montesarchio, V., Parella, R., Iommelli, C., Bianco, A., Manzillo, E., Fraganza, F., et al. (2020). Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J. Immunother. Cancer 8 : 1089.
Moores, L.K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J.F., Doerschug, K., et al. (2020). Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest 158 : 1143–1163.
Nadkarni, G.N., Lala, A., Bagiella, E., Chang, H.L., Moreno, P.R., Pujadas, E., et al. (2020). Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J. Am. Coll. Cardiol.76 : 1815–1826.
Nicolini, L.A., Mikulska, M., Signori, A., Biagio, A. Di, Portunato, F., Vena, A., et al. (2020). Reply to: “Antiviral activity and safety of darunavir/cobicistat for treatment of COVID-19”. Open Forum Infect. Dis. 7 :.
NIH (2020). Antithrombotic Therapy | COVID-19 Treatment Guidelines.
Niriella, M.A., Ediriweera, D.S., Silva, A.P. De, Premarathne, R., Balasooriya, P., Duminda, K.D., et al. (2020). Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: Study protocol for a randomized, controlled trial. Trials21 : 748.
Paranjpe, I., Fuster, V., Lala, A., Russak, A.J., Glicksberg, B.S., Levin, M.A., et al. (2020). Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J. Am. Coll. Cardiol. 76 : 122–124.
Pasquini, Z., Montalti, R., Temperoni, C., Canovari, B., Mancini, M., Tempesta, M., et al. (2020). Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. J. Antimicrob. Chemother. 75 : 3359–3365.
Pavoni, V., Gianesello, L., Pazzi, M., Stera, C., Meconi, T., and Frigieri, F.C. (2020). Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Thromb. Res.196 : 313–317.
Perrone, F., Piccirillo, M.C., Ascierto, P.A., Salvarani, C., Parrella, R., Marata, A.M., et al. (2020). Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J. Transl. Med.18 :.
Pizzini, A., Aichner, M., Sahanic, S., Böhm, A., Egger, A., Hoermann, G., et al. (2020). Impact of vitamin d deficiency on covid-19—a prospective analysis from the covild registry. Nutrients 12 : 1–9.
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med.
Qian, Z., Travanty, E.A., Oko, L., Edeen, K., Berglund, A., Wang, J., et al. (2013). Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am. J. Respir. Cell Mol. Biol. 48 : 742–748.
Rajter, J.C., Sherman, M.S., Fatteh, N., Vogel, F., Sacks, J., and Rajter, J.-J. (2020). Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019. Chest.
Rattanaumpawan, P., Jirajariyavej, S., Lerdlamyong, K., Palavutitotai, N., and Saiyarin, J. (2020). Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multi-center Observational Study. MedRxiv 2020.06.24.20133249.
Regeneron Pharmaceuticals, I. Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients | Regeneron Pharmaceuticals Inc.
Rinott, E., Kozer, E., Shapira, Y., Bar-Haim, A., and Youngster, I. (2020). Ibuprofen use and clinical outcomes in COVID-19 patients. Clin. Microbiol. Infect. 26 : 1259.e5-1259.e7.
Roche (2020). Roche - Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia.
Rojas, M., Rodríguez, Y., Monsalve, D.M., Acosta-Ampudia, Y., Camacho, B., Gallo, J.E., et al. (2020). Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun. Rev. 19 :.
Sadeghi, A., Ali Asgari, A., Norouzi, A., Kheiri, Z., Anushirvani, A., Montazeri, M., et al. (2020). Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J. Antimicrob. Chemother. 75 : 3379–3385.
Sanofi (2020a). Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly - Sanofi.
Sanofi (2020b). Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. - Sanofi.
Scavone, C., Brusco, S., Bertini, M., Sportiello, L., Rafaniello, C., Zoccoli, A., et al. (2020). Current pharmacological treatments for COVID-19: What’s next? Br. J. Pharmacol. 177 : 4813–4824.
Scialo, F., Daniele, A., Amato, F., Pastore, L., Matera, M.G., Cazzola, M., et al. (2020). ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung 198 : 867–877.
Scott, L.J. (2017). Tocilizumab: A Review in Rheumatoid Arthritis. Drugs77 : 1865–1879.
Sheahan, T.P., Sims, A.C., Leist, S.R., Schäfer, A., Won, J., Brown, A.J., et al. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11 :.
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., et al. (2020). Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA - J. Am. Med. Assoc. 323 : 1582–1589.
SHI, C., WANG, C., WANG, H., YANG, C., CAI, F., ZENG, F., et al. (2020). The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. Rappaport Fac. Med. 2020.03.28.20046144.
Shrestha, D.B., Budhathoki, P., Khadka, S., Shah, P.B., Pokharel, N., and Rashmi, P. (2020). Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol. J. 17 : 141.
Simonovich, V.A., Burgos Pratx, L.D., Scibona, P., Beruto, M. V., Vallone, M.G., Vázquez, C., et al. (2020). A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N. Engl. J. Med.
Skipper, C.P., Pastick, K.A., Engen, N.W., Bangdiwala, A.S., Abassi, M., Lofgren, S.M., et al. (2020). Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Ann. Intern. Med. 173 : 623–631.
Spinner, C.D., Gottlieb, R.L., Criner, G.J., Arribas López, J.R., Cattelan, A.M., Soriano Viladomiu, A., et al. (2020). Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 : 1048–1057.
Sterne, J.A.C., Murthy, S., Diaz, J. V., Slutsky, A.S., Villar, J., Angus, D.C., et al. (2020). Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis. JAMA - J. Am. Med. Assoc. 324 : 1330–1341.
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., et al. (2020). Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ 369 :.
The Florentine (2020). Covid-19: Monoclonal antibody treatment developed in Siena.
Tiberghien, P., Lamballerie, X. de, Morel, P., Gallian, P., Lacombe, K., and Yazdanpanah, Y. (2020). Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 115 : 488–494.
Tirupakuzhi Vijayaraghavan, B.K., Jha, V., Rajbhandari, D., Myatra, S.N., John, O., Ghosh, A., et al. (2020). Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: The HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial. Trials 21 : 754.
Tleyjeh, I.M., Kashour, Z., Damlaj, M., Riaz, M., Tlayjeh, H., Altannir, M., et al. (2020). Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis. Clin. Microbiol. Infect.
Tomazini, B.M., Maia, I.S., Cavalcanti, A.B., Berwanger, O., Rosa, R.G., Veiga, V.C., et al. (2020). Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA - J. Am. Med. Assoc. 324 : 1307–1316.
University of Oxford (2020a). Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial — RECOVERY Trial.
University of Oxford (2020b). Welcome — RECOVERY Trial.
US Food and Drug Administration (2020a). FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems | FDA.
US Food and Drug Administration (2020b). Recommendations for Investigational COVID-19 Convalescent Plasma | FDA.
Valle, D.M. Del, Kim-Schulze, S., Huang, H.H., Beckmann, N.D., Nirenberg, S., Wang, B., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26 : 1636–1643.
Voysey, M., Ann, S., Clemens, C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., et al. (2020). Articles Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet0 :
Wang, J., Nikrad, M.P., Phang, T., Gao, B., Alford, T., Ito, Y., et al. (2011). Innate immune response to influenza A virus in differentiated human alveolar type II cells. Am. J. Respir. Cell Mol. Biol. 45 : 582–591.
Wang, M., Wu, T., Zuo, Z., You, Y., Yang, X., Pan, L., et al. (2020a). Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. BMJ Support. Palliat. Care bmjspcare-2020-002554.
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., et al. (2020b). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395 : 1569–1578.
WATANABE, S., CHAN, M., SUZUKI, W., and Nikkei staff writers (2020). China says Japan-developed drug Avigan works against coronavirus - Nikkei Asia.
Wit, E. de, Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., et al. (2020). Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl. Acad. Sci. U. S. A. 117 : 6771–6776.
World Health Organization WHO recommends against the use of remdesivir in COVID-19 patients.
World Health Organization (2020a). Clinical management of COVID-19.
World Health Organization (2020b). Draft landscape of COVID-19 candidate vaccines.
World Health Organization (2020c). Solidarity clinical trial for COVID-19 treatments .
World Health Organization (2020d). WHO/Europe | Antimicrobial resistance - Preventing the COVID-19 pandemic from causing an antibiotic resistance catastrophe.
World Health Organization (2020e). WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19.
Worldometer (2020). Coronavirus Update (Live): 60,272,757 Cases and 1,418,260 Deaths from COVID-19 Virus Pandemic - Worldometer.
Wu, X., Yu, K., Wang, Y., Xu, W., Ma, H., Hou, Y., et al. (2020). Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial. Engineering.
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., et al. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U. S. A. 117 : 10970–10975.
Zemb, P., Bergman, P., Camargo, C.A., Cavalier, E., Cormier, C., Courbebaisse, M., et al. (2020). Vitamin D deficiency and the COVID-19 pandemic. J. Glob. Antimicrob. Resist. 22 : 133–134.
Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., et al. (2020a). Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest158 : e9–e13.
Zhang, X., Zhang, Y., Qiao, W., Zhang, J., and Qi, Z. (2020b). Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int. Immunopharmacol. 86 :.
Zhang, Z., Wang, S., Tu, X., Peng, X., Huang, Y., Wang, L., et al. (2020c). A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J. Med. Virol. 92 : 2631–2636.
Zhu, Z., Lu, Z., Xu, T., Chen, C., Yang, G., Zha, T., et al. (2020). Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J. Infect. 81 : e21–e23.